Can a new antibody help lupus patients ditch steroids?

NCT ID NCT07751848

Not yet recruiting Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This trial is testing whether anifrolumab, an experimental antibody, can help Chinese adults with moderate-to-severe systemic lupus erythematosus (SLE) achieve remission. Participants receive anifrolumab infusions over 52 weeks alongside standard care, with a focus on safely reducing or stopping steroid use. The study tracks how many people reach a defined remission state and how long they stay in it.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anifrolumab, an experimental antibody given by IV infusion, added to standard lupus care.
What this could lead to: If successful, this could support anifrolumab as a treatment option for Chinese lupus patients, potentially helping more people reach remission with less reliance on steroids.
What could go wrong: This is a single-arm, open-label study without a placebo, so results may be less definitive. Anifrolumab can have side effects like infections or allergic reactions, and not all patients may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUPUS ERYTHEMATOSUS, SYSTEMIC

Contacts and locations

Locations

Research Site

Beijing, 100053, China
Research Site

Beijing, 100191, China
Research Site

Beijing, 100730, China
Research Site

Bengbu, 233004, China
Research Site

Changchun, 130021, China
Research Site

Changchun, 130033, China
Research Site

Changsha, 410008, China
Research Site

Chengdu, 610072, China
Research Site

Guangdong Province, 510060, China
Research Site

Guangzhou, 510100, China
Research Site

Guangzhou, 510120, China
Research Site

Guangzhou, 510630, China
Research Site

Hangzhou, 310003, China
Research Site

Hangzhou, 310006, China
Research Site

Hangzhou, 310014, China
Research Site

Harbin, 150001, China
Research Site

Hefei, 230001, China
Research Site

Hengyang, 421001, China
Research Site

Hohhot, 750306, China
Research Site

Jinan, 250021, China
Research Site

Kunming, 650032, China
Research Site

Luoyang, 471003, China
Research Site

Nanchang, 330000, China
Research Site

Nanchong, 637000, China
Research Site

Nanjing, 210000, China
Research Site

Nanjing, 210009, China
Research Site

Nanning, 530000, China
Research Site

Nantong, 226001, China
Research Site

Qingdao, 266035, China
Research Site

Shanghai, 200001, China
Research Site

Shanghai, 200032, China
Research Site

Shanghai, 200040, China
Research Site

Shenyang, 110134, China
Research Site

Suzhou, 215006, China
Research Site

Tianjin, 300050, China
Research Site

Ürümqi, CN-830004, China
Research Site

Wenzhou, 325000, China
Research Site

Wuhan, 430022, China
Research Site

Wuhan, 430030, China
Research Site

Wuhan, 430060, China
Research Site

Xi'an, 710077, China
Research Site

Xiamen, 361003, China
Research Site

Yangzhou, 225001, China
Research Site

Zhengzhou, 450000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.